Sally is responsible for researching a range of healthcare, consumer staples and chemicals stocks.

​

Sally has over 28 years’ experience in investment markets and medicine.  Previous roles include global equity analysis at Platinum Asset Management, Australian equity portfolio management and analysis at Credit Suisse Asset Management and managing portfolios for a private investment company.  Sally has also held analyst roles in healthcare and chemicals at Merrill Lynch (Australia) and BBY.

​

Sally brings significant expertise in healthcare and biotechnology, with previous roles including research, specialising in cancer and immunology where she gained her PhD, HIV therapies and as a board member of the Health Insurance Commission when it was responsible for administering Australia’s Medicare and Pharmaceutical Benefits Scheme.